American Shared Hospital Services (AMS)

From our perspective at the desk, AMS's recent Q2 2026 numbers show a clear operational inflection. Total revenue jumped 19% year-over-year to $8.4 million, driven primarily by a 40% surge in Direct Patient Services revenue. The market is starting to validate their strategic pivot away from legacy equipment leasing toward a high-margin, own-and-operate radiation oncology platform footprint.

Looking at the small-cap research coverage from Zacks, the liquidity extension and expanded OandO footprint are providing a supportive floor. However, as risk managers, we note that despite top-line growth, the company previously posted a net loss in Q1 2026 with an EPS loss of $0.09. Sustaining operational profitability remains crucial before broader institutional capital steps in meaningfully.

Tracking retail sentiment and recent filings via Form 10-Q and 8-K, AMS trades as a micro-cap with a market cap hovering around $9.47 million. While retail discussion spikes around earnings releases like the August report, volatility remains elevated, requiring strict position sizing for market participants engaging with the name.

In our clinical and technical evaluation of advanced radiation therapy infrastructure, the international deployment is yielding tangible results. Specifically, the ESPRIT Gamma Knife technology upgrade in Peru has significantly optimized patient treatment workflows and outcomes, directly supporting international performance gains alongside their operations in Rhode Island.

Evaluating their business model shift, transitioning from passive equipment leasing to active direct patient service provision requires rigorous clinical oversight and localized operational execution. The early returns in Rhode Island and Peru indicate that their execution playbook is scaling effectively within radiation oncology.